Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) Amortization - Intangibles (2023 - 2025)

Historic Amortization - Intangibles for Regen BioPharma (RGBP) over the last 3 years, with Q3 2025 value amounting to $14231.0.

  • Regen BioPharma's Amortization - Intangibles fell 1079.42% to $14231.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $52148.0, marking a year-over-year increase of 7983.31%. This contributed to the annual value of $52148.0 for FY2025, which is 7983.31% up from last year.
  • Regen BioPharma's Amortization - Intangibles amounted to $14231.0 in Q3 2025, which was down 1079.42% from $12639.0 recorded in Q2 2025.
  • In the past 5 years, Regen BioPharma's Amortization - Intangibles ranged from a high of $15953.0 in Q3 2024 and a low of $4339.0 during Q1 2024
  • For the 3-year period, Regen BioPharma's Amortization - Intangibles averaged around $10143.2, with its median value being $12639.0 (2024).
  • The largest annual percentage gain for Regen BioPharma's Amortization - Intangibles in the last 5 years was 19128.83% (2025), contrasted with its biggest fall of 1079.42% (2025).
  • Regen BioPharma's Amortization - Intangibles (Quarter) stood at $4367.0 in 2023, then soared by 189.42% to $12639.0 in 2024, then rose by 12.6% to $14231.0 in 2025.
  • Its last three reported values are $14231.0 in Q3 2025, $12639.0 for Q2 2025, and $12639.0 during Q1 2025.